Patent ID: 9285370
Filing Date: 2016-03-15
CPC Classification: A61K,A61P,C07K,G01N

Claim Text:
1. A method for treating metastatic breast cancer in a subject in need of treatment, the method comprising administering to the subject a therapeutically effective amount of an ADAM22 (a disintegrin and metalloproteinase protein 22) inhibitor, wherein the ADAM22 inhibitor inhibits migration of breast cancer cells, and wherein the ADAM22 inhibitor is selected from the group consisting of: (A) a leucine-rich, glioma-inactivated protein 1 (LGI1) of SEQ ID NO: 1; and (B) a LGI1 peptide mimic comprising the ADAM22 binding domain of LGI1 (SEQ ID NO: 3), or a functional fragment thereof having at least 15 amino acids, or functional variants of the fragment having at least 90% sequence identity with the fragment, wherein the LGI1 peptide mimic binds to the LGI1 binding domain of ADAM22.